Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 4/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467657 | 1.00 | CXCR2 (0.33) | CXCR2PREPPDE10AF2PRSS1 | |
| SCHEMBL24252298 | 0.92 | F2 (0.31) | CXCR2F2PRSS1 | |
| SCHEMBL30467698 | 0.92 | F2 (0.31) | CXCR2F2PRSS1 | |
| SCHEMBL30467635 | 0.90 | PDE10A (0.33) | CXCR2PREPPDE10AF2PRSS1 | |
| SCHEMBL24252494 | 0.90 | PDE10A (0.33) | CXCR2PREPPDE10AF2PRSS1 | |
| SCHEMBL24252641 | 0.88 | PDE10A (0.33) | PREPPDE10AF2PRSS1 | |
| SCHEMBL30467753 | 0.88 | PDE10A (0.33) | PREPPDE10AF2PRSS1 | |
| SCHEMBL24252280 | 0.88 | PDE10A (0.33) | PREPPDE10AF2PRSS1 | |
| SCHEMBL30467666 | 0.88 | PDE10A (0.33) | PREPPDE10AF2PRSS1 | |
| SCHEMBL24252622 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CXCR2 3401/4885PREP 456/4885PDE10A 1950/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CXCR2 3401/4885PREP 456/4885PDE10A 1950/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | CXCR2 3401/4885PREP 456/4885PDE10A 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.